Abstract: Enormous progress in the field of vaccine development has moved the area from traditional vaccines using whole microorganisms to subunit vaccines containing only purified or modified antigenic proteins. The low immunogenic potentials of subunit vaccines compared to live attenuated pathogens, have prompted the research towards developing new adjuvants with the ability to mimic and enhance the innate and adaptive immune responses. Novel adjuvants formulations based on the discovery of pattern recognition receptors (PRRs), the main class of innate immunity sensors have recently gained interest. The major family of PRRs called Toll-like receptors (TLRs), which are expressed by a variety of cells and capable to induce innate immune responses and effective stimulation of transition from innate immune responses to adaptive immune responses. PRR ligands of natural and synthetic origin have been evaluated as potential adjuvants in a variety of applications including vaccine formulations. Apart from this, for generating effective and protective immune responses, targeted delivery of vaccine antigens along with PRR agonists to the desired cells is of great importance. New strategy of delivering vaccine antigens along with adjuvants using proper nano-sized materials has gained much attention during the recent years. Here we review the recent advances regarding PRR-based nano-adjuvants developments, focusing on current nano-materials based delivery system and their applications in biomedical sciences.
INTRODUCTION
Vaccination has proven to be one of the greatest achievements in the history of medical sciences. Since it was introduced by Edward Jenner in the 18th century, and developed by Louis Pasteur a century later, it has been the most effective biomedical intervention against infectious diseases [1] . Generally, vaccination works by initiating and amplifying the immune responses against a specific agent, in order to rapidly recognize, respond and remove the threat on a later exposure. The innate immune system works by sensing the conserved sets of molecular patterns expressed by pathogens and endogenous danger signals through a diverse membrane bound and intracellular receptors called pattern recognition receptors (PRRs) [2] . These receptors are categorized to several families, including, toll like receptors (TLRs), C-type lectin receptors (CLRs), retinoic acidinducible gene I (RIG-I) helicases, nucleotide-binding oligomerization domain-like receptors (NLRs), which include inflammasome complexes [3] . The molecular patterns present in pathogenic microorganisms like, bacteria, viruses, parasites and fungi are called pathogen associated [4] . Upon recognition of PAMPs and DAMPs by PRRs, a cascade of intracellular signaling pathways is initiated leading to the activation and translocation of transcription factors like nuclear factor kappa B (NF-B) and interferon regulatory factors (IRFs) to the nucleous, promoting the production and secretion of pro-inflammatory cytokines and chemokines [4] (Fig. 1) . The local inflammatory responses initiated by the engagements of PRRs and their respective ligands (PAMPs, DAMPs) lead to the recruitment and maturation of sentient dendritic cells into the draining lymph nodes promoting the development of adaptive immune responses and ultimately creating an immunological memory [4] .
Although vaccination using whole inactivated or live attenuated microorganisms has led to the eradication of pandemic diseases like smallpox and a drastic reduction of other diseases such as polio and measles, many shortcomings were associated with these traditional vaccines [5] . With the advent of new technologies, the area of vaccine development has progressed enormously and has moved from whole microorganisms to subunit vaccines that contain only purified or modified antigenic proteins [6] . Subunit vaccines are often less immunogenic than live attenuated pathogens, therefore, adjuvants (from the Latin word adiuvare, to aid) can be incorporated into vaccine formulations in order to improve the vaccine efficacy by amplifying and enhancing the innate and adaptive immune responses [6] . Apart from designing the adjuvants, the system to deliver them into the desired cells is also of great importance [7] . Targeting the PRRs and especially TLRs as the first line of defense is the central feature of many adjuvants systems. Controlled delivery of PRR ligands using nanotechnology is a new strategy to manipulate the immune responses through vaccination [8] .
The immunostimulatory compounds used in combination with a specific antigen to trigger protective immune responses are indicated as vaccine adjuvants. Presence of an adjuvant in a vaccine results in eliciting the most protective and telling immune response promoting host defense [8] . Given the pivotal role of such components in optimizing vaccine efficacy, designing and development of new generations of adjuvants for translational medicine is eagerly awaited. With the advent of nanotechnology in vaccine research, an evolutionary advances occurred and paved the way for development of tunable adjuvants with highly function and safety [9] .
Nanotechnology as a science dealing with nanoscale molecules has influenced a broad range of sciences. It has shown that assembling nano-scale materials can generate important breakthroughs [9] . Up to now, various forms of nano-material products have been designed to deliver toxic drugs with minimum side effects, as well as incorporate adjuvants enhancing quantity and quality of immune responses during vaccination [9] . Exploiting nanotechnology has evolved to development of nano-structured materials by which release, degradation and cellular uptake of antigens can finely be controlled [9] . Nanotechnology helps researchers to manipulate and insert new properties into biomaterials for providing proper adjuvants. In this regards, designing nano-materials resembling virus properties both in structure and behavior has shown significant capability in stimulating innate immunity such as TLRs [9, 10] . In addition to stimulation of surface receptors, there are nanobased particles initiating inflammatory reactions via cell penetration and activation of intracellular receptors. For instance, incorporation of ligands into nano-adjuvants targeting endosomal TLRs and inflammasomes results in maturation and recruitment of antigen presenting cells (APCs) (Fig. 2) [9, 10] . Thus, nano-based adjuvants with both antigen delivery and immunostimulatory function can significantly increase vaccine efficacy in the clinical arena. An increasing body of data exists to show nano-based adjuvants can significantly amplify and direct immune responses to combat against wide arrays of infectious and immune-related diseases [5, [8] [9] [10] .
By nano-adjuvants we refer to the controlled delivery of immunostimulatory molecules like TLR agonists via nanomaterials to the specific immune cells. In this review, we aim to explore the most recent advances in the field of PPRs based immune adjuvants along with special focus on the development and applications of novel nano-sized based delivery vehicles in order to enhance the vaccine immunogenicity.
PRR-BASED IMMUNE ADJUVANTS
It is well established that immunization with a specific antigen in the absence of an adjuvant leads to eliciting low antibody production and T cell response [5, 6] . Furthermore, lack of an eligible adjuvant in vaccine composition requires Fig. (1) . Schematic depiction of pathways by which nano-based adjuvants can target PRRs in DCs. Stimulation of DCs with nano-adjuvant formulations (PRR agonists) trigger innate sensors including TLRs, CLRs, RLRs, NLRs, and DNA sensors, inducing secretion of inflammatory cytokines and type-I IFNs. Nano-vehicle systems can efficiently deliver antigens to major histocompatibility complex (MHC). They can also escape into the cytosol after phagosome uptake and stimulate intracellular receptors, amplifying cytokine secretion and upregulation of co-stimulatory molecules. repetitive immunizations. Presence of an adjuvant in a vaccine benefits the efficacy of immunization through dose sparing, eliciting a broad antibody production, optimization of immune responses with high quality and quantity, and acceleration of the immune responses [5] [6] [7] .
Given the central role of PRRs in maturation and activation of APCs, they have greatly been investigated to develop an effective adjuvant [11] . Nearly all PRRs and especially TLRs can be considered as the potential targets for designing immunostimulatory adjuvants to improve vaccine immunogenicity. The intracellular events elicited by PRRbased adjuvants enforce adaptive immune responses and subsequent immune protection, especially via stimulation of APCs and T cells [11] .
PRRs comprise wide ranges of intracellular and extracellular sensors signaling via multifactorial pathways upon recognition of conserved molecular patterns on invaders called PAMPs. Apart from PAMPs, PRRs are able to recognize host-derived components that stem from injured cells known as DAMPs [4] . Signaling cascades induced by PRRs ultimately evolve to produce inflammatory mediators such as cytokines, chemokines, prostaglandins, and reactive oxygen species, along with up-regulation of co-stimulatory molecules [4] .
Currently, a large number of preclinical studies are being performed to understand the basis of adjuvant activity of natural ligands or synthetic agonists of PRRs, to be used to develop therapeutic and prophylactic vaccines [12] . Also, many clinical trials are ongoing to evaluate their capability in clinical situations. Some of these adjuvants have been approved for application in human vaccines, such as monophosphoryl lipid A (MPLA) [12] .
CLRs sense the carbohydrate structures on pathogens. TLRs can recognize lipids, lipoproteins, nucleic acids, and proteins, while NLRs detect a variety of molecules/agents including peptidoglycan species, toxins, uric acid, and ATP [4] . Upstream and downstream signaling pathways activated by these receptors directly and indirectly support the activation of APCs at the site of vaccine administration and optimize the process of antigen uptake. Thus, incorporation of PRR stimulators in vaccine formulations can substantially culminate innate immunity and expedite vaccine-specific responses [12] . Here, we discuss on the efficacy of TLR, CLR, and NLR ligands as adjuvants when incorporated into nano-based carriers.
POTENTIAL OF CELL SURFACE INNATE RECEPTORS FOR ADJUVANT DEVELOPMENT

C-type Lectin Receptors (CLRs)
The CLR family comprises various types of receptors including DC-SIGN, DEC-205, Dectin-1 and 2, and Mincle [13] . CLRs are transmembrane receptors responding to carbohydrate structures such as glucan and mannose, which are represented by various pathogens [13] . Ligation of such structures to CLRs results in an endocytosis process that improves antigen presentation and elicits appropriate immune responses [13] . Furthermore, some CLRs such as Mincle and DC-SIGN are able to activate the NF-B pathway, whereby enhancing the production of inflammatory cytokines in APCs (Fig. 1 ) [13] .
It has been shown that stimulation of CLRs in dendritic cells (DCs) by nano-sized materials can significantly optimize antigen processing and presentation [14] . In this regard, incorporation of mannose into liposomes was found to strongly promote internalization by human DCs in comparison with native liposomes [14] . This result has also been reported for murine macrophages exposed to materials containing -glucan. Targeting Dectin-1 via oral and intradermal administration of vaccine containing these fungal-derived molecules provided high levels of antigenspecific antibodies [14] . Interesting results have also been obtained by targeting DEC-205 by poly(d,l-lactic-co-glycolic acid) (PLGA). Delivering antigens to DCs by DEC-205-labeled PLGA showed promising outcomes such as increase of CD4 + and CD8 + T cells and elevation of cross-presentation ( Table 1 ) [15] . Interestingly, application of -glucan extracted from Saccharomyces cerevisiae strongly induced Th1 and Th17 responses, suggesting incorporation of CLR agonists into vaccine formulation can markedly elicit the desired immune response [16] . In support of this, inclusion of CAF01 (a liposome-based adjuvant system to stimulate Mincle) into a vaccine against Mycobacterium tuberculosis (MTB) was found to elicit strong T cell immunity in a clinical trial [17] . Stimulation of Mincle with a vaccine containing MTB-derived antigen along with the CAF01 adjuvant also provided strong Th1 and Th17 responses in the mouse [16] .
TLRs
Induction of memory responses during vaccination is an essential factor, as vaccine developers are being focused to design appropriate formulation of vaccine complex for optimizing the memory cells production [18] . TLR ligands have widely shown their efficacy in amplification and eliciting memory T cell responses. Identifying the molecular mechanisms by which TLR agonists induce memory B and T cells has encouraged the investigators to develop new TLRbased immune adjuvants [19] . A large body of literature has suggested that TLR agonists can be exploited to formulate an adjuvant platform both in combination with other components and alone, to establish an effective immune protection after vaccination [19] .
TLRs are located both on plasma membrane (such as TLR1, 2, 4, 5, 6) and endosomal compartments (such TLR3, 7, 9). Various adaptor molecules such as myeloid differentiation primary response gene 88 (MyD88) are recruited by the TLR intracellular domain [20] . Activation of downstream cascades evolves to upregulate different transcriptional factors in DCs that provide the specific cytokine milieu for polarization of naïve CD4 T cells toward Th1, Th2, Th17, and regulatory T cells (Treg) [20] . Activation of TLRs in B cells was found to increase the expression of surface molecules associated with antigen presentation (MHC I and MHC II) and T cell priming (CD40, CD80, CD86). Production of antigen-specific antibody is increased after TLR stimulation in B cells, and TLR targeting can induce B and T cell memory [20] .
While TLR2 heterodimers (TLR1/2 and TLR2/6) and TLR5 preferentially direct T cell responses toward Th2, other TLRs (including TLR3, TLR4, TLR7, TLR8 and TLR9) trigger pathways supporting Th1 responses [20] .
Most immune cells are able to express PRRs, especially TLRs recognizing conserved biomolecules existing in a broad range of pathogens [21] . Many investigations have proved that TLR stimulation can significantly affect the process of uptake and presentation of antigens by APCs. Importantly, the quality and quantity of adaptive immune response induced by DCs are highly depending on TLRs stimulation [22] . It has been indicated that stimulation of DCs with synthetic form of TLR3 agonists (Poly I:C) potentiates cross-presentation in DCs and cellular immunity via amplification of CD8 + T cells [22] . Activation of downstream pathways upon TLR stimulation enhances the production of inflammatory mediators (cytokines and chemokines) and up-regulation of co-stimulatory molecules, providing the conditions for appropriate priming, expansion, and polarization of adaptive immune responses [23] . Indeed, the capability of microbial-derived and synthetic types of TLR stimuli to redirect adaptive immune responses makes them attractive adjuvant candidates for incorporation both therapeutic and protective vaccines [23] . The delivery platforms using proper nanomaterials to carry the TLR ligands along with the vaccine antigen(s) to their target cells are also of great importance, which is discussed further and summarized in Table 1 .
Surface TLRs
TLR1/2 and TLR2/6 Ligands
TLR2 is able to dimerize with either TLR1 or TLR6. A wide range of natural agents/molecules (mostly microbial)is recognized by TLR2 heterodimers, such as the M. fermentans macrophage-activating lipopeptide (MALP-2) [24] . Among the synthetic molecules stimulating the TLR2 heterodimers, the triacylated lipoprotein Pam3CSK4 (TLR2/TLR1 ligand) and the diacylated lipoprotein Pam2CSK4 (TLR2/TLR6 ligand) have been used in several studies [24] . Interestingly, TLR2 signaling preferentially directs the immune response towards Th2. Also, agonists targeting TLR2 activate DCs and B cells to amplify antigenspecific CD8 + cytotoxic T cell (CTL) responses [25, 26] . However, depending on the type of TLR2 heterodimer the major immune response elicited can be differed [27, 28] . In support of this, it has been reported that TLR1/TLR2 supports both mucosal Th17 response and Treg expansion, whereas TLR2/TLR6 pathway may induce tolerogenic DCs and Treg responses [27, 28] . The adjuvant activity of MALP-2 has been reported in both experimental models and in combination with antigens such as ovalbumin (OVA) [29] . Co-administration of MALP-2 with vaccine antigens is able to properly induce both humoral and cellular immunity including production of IFN-, IL-2, IL-4, antigen-specific serum IgG, and mucosal IgA [29] . LYMErix® and Theradigm-hepatitis B virus (HBV) are two licensed vaccines in which TLR2 stimulating adjuvants play an essential role in their efficacy against Lyme disease and hepatitis B, respectively [30] .
Several nanomaterial vehicles such as liposomes have been used to deliver TLR1/2 and TLR2/6 adjuvants in combination with vaccine antigens (Table 1) [31] . It was found that incorporation of palmitoyl chain (Pam) diacylated and triacylated lipopeptides (Pam2CAG and Pam3CAG agonists of TLR1/2 and TLR2/6, respectively) into liposomes can effectively result in DC maturation and antigen presentation [31] .
TLR4 Ligands
A well-recognized ligand for TLR4 is the bacterial lipopolysaccharide (LPS) that strongly triggers acute inflammatory responses by inducing inflammatory cytokines such as TNF-and IL-1 . Owing to induction of deleterious inflammatory reactions, LPS has been ruled out as potential adjuvant for human use, and non-toxic LPS derivatives, such as monophosphoryl lipid A (MPLA) derived from Salmonella minnesota, were introduced as alternative TLR4 agonists [32] . There is a key difference between the signaling pathways of LPS and MPL that accounts for the toxic effects of LPS in comparison with MPLA [32] . In fact, it has been unraveled that upon ligation of LPS to TLR4 both TIR-domain-containing adaptor-inducing interferon-(TRIF) and MyD88 adaptor proteins are recruited, while MPLA just signals via the TRIF pathway. The principal cause for upregulation of inflammatory cytokines during LPS administration is attributed to activation of the MyD88 pathway [32] . Furthermore, experimental data suggest that combination of MPL and alum (AS04) can amplify Th1 cells [33] . Application of MPLA as an adjuvant for the HBV vaccine has been approved in Europe and Argentina [34] . In addition, several clinical trials have been launched to evaluate the effectiveness of other TLR4 ligands. Although promising results have been obtained, much still remains to be learnt. Nano-based vehicles are widely being used to control delivery and release of TLR4 agonists to desired sites [35, 36] . Exploiting nano-based carrier systems, including PLGA and liposomes, to deliver LPS causes elevation of antigenspecific antibody production [35, 36] . In addition, it has been shown that incorporation of antigens into PLGA coated with LPS optimizes antigen uptake by DCs, and improves cellular and humoral immunity [36] . In this regard, Demento et al. showed that incorporation of recombinant peptides derived from West Nile virus envelope into PLGA loaded with LPS can significantly enhance internalization by DCs in comparison with LPS-free PLGA [36] . In this study, the authors indicated that this PLGA-based vaccine can protect mice from West Nile encephalitis. It has been suggested that the major mechanism by which this LPS-coated PLGA induces potent innate and adaptive responses depend on NOD-like receptor protein 3 (NLRP3) [36] . Liposomes and PLGA have also been used to deliver antigens along with MPLA in vaccine development [37] . For example, Stimuvax was a vaccine containing MPLA incorporated in liposome, which was designed against non-small cell lung carcinoma for human application. However, its clinical trial (NCT01015443, NCT00409188) was terminated in phase III.
TLR5 Ligands
It is known that flagellin from many bacteria binds to TLR5 and triggers activation pathways leading to the production of inflammatory cytokines [38] . Thus, also TLR5 ligands are potential candidates for adjuvant development [39] . Flagellin, both in combination and fused with vaccine antigens, can increase immunization efficacy, and elicits a mixture of both Th1 and Th2 responses. However, due to strong activation of NF-B, a Th2 biased response is mostly dominant [38, 39] .
The ability of flagellin to induce an appropriate humoral immunity and antibody production is highly dependent on TLR5 and MyD88 expression [38] . As indicated in many experimental studies, flagellin possesses significant immunostimulatory functions such as up-regulation of surface molecules (CD80, CD86, MHC II) leading to DCs maturation and stimulation, as well as it induces IFN-, IL-10, and TNF-production via natural killer cells (NKs), CD8
+ T cells and APCs [39] .
Inclusion of flagellin as an adjuvant in influenza vaccines was associated with significant protective immunity in mice [40, 41] . Further preclinical studies suggested that the adjuvant activity of flagellin can be optimized by fusion with viral antigens [40] . The VAX125 and VAX128 vaccines consist of flagellin molecules that are conjugated with hemagglutinin. In the VAX102 vaccine, flagellin has been fused with matrix protein 2 ectodomain (M2e) [40, 41] . In addition to infectious diseases, flagellin has received significant attention in cancer immunotherapy as it elicits strong tumor-specific CD8 + T cell responses [39] . A part from TLR5, flagellin can bind to the nucleotide oligomerization domain like receptor (NLRC4), which is an inflammasome complex. However, how much NLRC4 activation contributes to the adjuvant activity of flagellin remains elusive [42] .
Thus, inclusion of flagellin in vaccine complex can significantly activate innate immunity and strong immune responses, due to co-stimulation of both TLR5 and NLRC4 [42] . Nano delivery of flagellin using polyanhydride and polypropylene sulfide nanoparticles has been reported ( Table  1 ) [43] . Conjugation of flagellin to these nano-carriers was found to promote both Th1 and humoral immune responses against specific antigen [43] . Some vaccines containing flagellin are currently being investigated in clinical conditions and up to now no serious side effects have been reported [44] .
Potentials and Possibilities of Intracellular Receptor Agonists as Vaccine Adjuvants
Inflammasomes are intracellular protein complexes formed in response to both PAMPs and DAMPs [45] . NLRs are localized in the cytosol; upon recognizing their ligands during conformational changes can trigger multifarious downstream pathways [45] . Among various types of inflammasomes the potential adjuvant activity of NLRP3, RIG-I, and melanoma differentiation associated gene 5 (MDA5) ligands has been reported [45] .
Phagocytosis of crystalline-like components such as uric acid crystals, which damage lysosomal membrane and escape to cytosol, can stimulate NLRP3 [45] . In addition, dead cell-derived molecules including ATP (defined as DAMP) connecting cellular injury to inflammation can also stimulate NLRP3. The activity of the adjuvant alum, whose efficacy has long been recognized and is approved for human use, could be due to NLRP3 inflammasome activation, although results in the literature are conflicting [see for instance ref. 46].
NLRs
The NLRP3 inflammasome is a multiprotein complex that activates caspase-1, which converts pro-IL-1 and pro-IL-18 to their bioactive forms [45] . Currently, several biomaterials such as PLGA and chitosan (a polysaccharide found in the exoskeletons of crustaceans and in the cell walls of fungi) have been used to deliver NLRP3 inflammasome activators as immunoadjuvants ( Table 1 ) [47] [48] [49] . In addition, such nanoparticles are able to stimulate the NLRP3 inflammasome even without carrying known NLRP3 activators [48, 49] . This suggests that these nanoparticles could induce the release of DAMPs and consequent inflammasome activation [47, 48] .
Aside from NLRPs, other intracellular sensors belonging to the NOD-like receptor family are the nucleotide binding oligomerization domain proteins (NODs) [3] . The potential Hepatitis B virus antigens -------adjuvant activity of their agonists has been shown when incorporated with nanomaterials such as liposomes [50] . Activation of NOD1 and NOD2 promotes the production of inflammatory cytokines and chemokines via the mitogenactivated protein kinases (MAPK) and NF-B pathways, thereby up-regulating co-stimulatory molecules and optimizing antigen presentation [3] . Nano delivery of NOD agonists through incorporation into liposomes induces effective cellular and humoral responses ( Table 1 ) [50] .
TLR3
TLR3 and RIG-I-like receptors (RLRs), such as MDA5, are able to recognize viral dsRNA and subsequently activate transcription factors, such as interferon regulatory factor 3(IRF3/7) and NF-B, that upregulate type I interferons (IFNs) [51] . These cytokines potentiate cellular and humoral immunity by targeting a wide array of immune cells such as APCs, NK cells, and T cells [51] . Production of type I IFNs upon stimulation of TLR3 in DCs leads to up-regulation of MHC class II expression and heightening antigen presentation [51] .
Targeting these receptors by synthetic analogs of dsRNA (poly I:U and Poly I:C) as adjuvants along with vaccine antigens has provided promising results both in preclinical and clinical studies [52] . It has been proposed that poly I:C has more adjuvant activity than poly I:U, this difference being attributed to the fact that poly I:C is able to stimulate both TLR3 and MDA5, while poly I:U only activates TLR3 [52] . Co-stimulation of these receptors increases longevity of cellular immunity mediated by Th1 and CD8 + T cells, indicating the efficacy of poly I:C as an adjuvantable to induce vaccine-derived memory responses [52] . It has been proved that incorporation of these synthetic products into nanoparticle delivery systems such as PLGA can significantly enhance DC maturation and proliferation of antigen specific CD8 + T cell ( Table 1 ) [53] .
TLR7 and TLR8 Ligands
TLR7 and TLR8 are responsible for detection of viral single stranded RNA(ssRNA) molecules [51] . They activate signaling pathways elevating the expression of costimulatory molecules, production of type I IFNs and IL-12 [51] . Since it was found that stimulation of these receptors in DCs strengthens immunogenicity to the antigens, many preclinical and clinical studies were planned to evaluate the adjuvanticity of synthetic products in vaccine design [52] . Imiquimod and resiquimod are well-known small synthetic molecules that stimulate the TLR7 and TLR7/TLR8, respectively [51] . The immunostimulatory functions of these synthetic analogs had widely been proved in preclinical studies. Due to favorable results in clinical trials, imiquimod was approved by FDA to treat human papillomavirus (HPV)-induced genital and perianal warts [51] .
DCs and B cells exposed to TLR7 and TLR8 agonists induce strong Th1 response, antibody production, and cross presentation [51] . The immunostimulatory function of resiquimod is more potent than imiquimod because the latter analog just stimulates TLR7, whereas resiquimod is a bispecific compound targeting both TLR7 and TLR8 [54] . There is evidence suggesting that simultaneous coadministration of these molecules and antigens without any conjugation does not result in significant adjuvant activity, indicating the importance of formulation and mode of delivery for optimal adjuvanticity [55] . As compared to other TLR agonists, limited data are available concerning the delivery of TLR7 or TLR8 agonists by nano-based vehicles. However, the potential of liposomes and PLGA as carrier systems to deliver these agonists has been reported [55] .
TLR9 Agonists
Stimulation of TLR9 has long been one of the most promising options for optimizing immunization, and it has been extensively investigated both in animal experiments and clinical studies [51] . CpG oligodeoxy nucleotides (CpG-ODN) are the best-known synthetic form of TLR9 agonists, and have shown good adjuvant activity in many studies [56, 57] . Just like for other endosomal TLRs, TLR9 signaling supports Th1 responses and optimizes antibody production. Stimulation of TLR9 is associated with production of inflammatory cytokines including IL-6, IL-12, and IFN-, as well as expression of co-stimulatory molecules involved in the interaction of APCs with T cells [57] . TLR9 is significantly expressed in B cells, and its stimulation results in enhancement of antigen-specific humoral immune responses and Ig class switching [51, 56, 57] . The efficacy of CpG ODN as vaccine adjuvants for human use has been shown in several cases. For instance, the use of CpG-ODN in the Engerix-B® and Heplisav® vaccine formulations improved protective immune responses against HBV by inducing long-term antibody responses [58, 59] . In addition, adding CpG ODN in influenza vaccines such as Fluarix® increased IFN-production, thereby allowing reducing the antigen dose and the frequency of vaccine administration [60] .
There is solid evidence showing that incorporation of CpG-ODN into nano-based delivery systems can efficiently improve vaccine-specific immune responses [61] . In addition, it has been shown that PLGA coated with CpG and encapsulating West Nile virus protein antigens induced effective protection against the viral infection by promoting humoral and cellular responses [62] . In this study it was found that immunization of mice with CpG-coated PLGA shapes immune responses toward Th1 and proliferation of T cells, while administration of aluminum hydroxide or unmodified PLGA alone elicits Th2 responses, suggesting the critical role of nano-based carriers for development of effective vaccine adjuvants [62] .
MULTIPLE TLR AGONIST FORMULATIONS: A POTENTIAL APPROACH TO BOOST IMMUNE RESPONSES AND VACCINE IMMUNOGENICITY
Due to existence of multiple intracellular cross talks between innate receptors, simultaneous stimulation of several innate sensors is expected to be more efficacious than stimulation of single receptors [63] . Co-activation of several TLRs in DCs can synergistically enhance the production of inflammatory cytokines [63] . In this regard, a clinical trial (NCT00675727) was launched in 2006 to evaluate the efficacy of a poly-TLR activation as adjuvant approach in a therapeutic vaccine against melanoma [64] . This vaccine (known as CADI-05) was a poly-TLR poly-antigenic complex administered intradermally to patients with end stage melanoma. Although the vaccine had effect on some of the patients in phase I and II clinical trials, the trials were terminated in 2010 because of safety concerns [64] .
Many in vitro and in vivo studies have documented that using a combination of TLR agonists is more effective than using single agonists [63] . In addition, the promising results obtained with an MPL-alum complex or MPL in liposome (AS01) suggest that the strategies by which a potential adjuvant is delivered can significantly affect antigen uptake and presentation by DCs [65] . Also, it has been shown that incorporation of CpG along with multiple PRR agonists into single vehicle system potentiates immune responses [66] . For instance, a clinical trial (NCT00952692) evaluating the efficacy of a therapeutic cancer vaccine (AS15) showed that co-incorporation of three different adjuvants (CpG, MPLA, and the saponin derivative QS21) into liposomes can boost the anti-cancer immune responses. In light of these promising results, additional preclinical studies are expected so as to achieve optimized adjuvant formulations of multiple PRR agonists.
PRR-BASED NANO-ADJUVANT DELIVERY SYSTEMS
Delivery systems such as carbon nanotubes (CNTs), PLGA, polyethylenimine (PEI), liposomes and virus-like particles (VLPs) have been extensively explored for adjuvant delivery [67, 68] .
Carbon Nanotubes
The application of carbon nanotubes (CNTs) in nanomedicine is progressing rapidly [69] . CNTs are tubular structures composed entirely of carbon atoms arranged in benzene rings forming graphite sheets. Depending on the number of layers of rolled graphite sheets they can be categorized into Single-Walled Carbon Nanotubes (SWNTs) and Multi-Walled Carbon Nanotubes (MWNTs) [70] .
There are a number of features that make CNTs an attractive candidate material for a wide range of studies,including drug delivery [70, 71] , vaccine and adjuvant delivery [67, 72, 75, 76] , DNA and protein biosensing [75] , and highly specific detection of autoantibodies in human autoimmune diseases [76] . CNTs are almost chemically inert and non-immunogenic [74, 77] . Cationic-functionalized CNT (f-CNT) are one of the main delivery system for unmethylated CpG ODN, because of their capacity to facilitate their cellular uptake [73, 78] . Bianco et al. showed that ammoniumfunctionalized SWNTs could successfully condense DNA, and used two types of cationic f-CNT to evaluate their interaction with CpG ODN (TLR9 agonist). The results showed that f-CNT have the ability to improve the immunostimulatory properties of CpG ODN and have no unwanted effect on activated or non-activated lymphocytes [73] . CNTs can easily and rapidly enter into cells like macrophages, monocytes, natural killer (NK) cells, DCs, B and T cells, all fundamental for stimulation of effective immune responses [79] [80] [81] . CNTs did not impair the functionality of these cells, especially in the form of f-CNT [79, 82] . In another study, a selective endosomal TLR7 agonist (7-thia-8-oxoguanosine, 7-TOG) was covalently attached to previously oxidized MWNTs, and tested for the ability to activate human monocyte-derived DCs. Efficient phagocytosis of the 7-TOG-MWCNT conjugate by DCs was achieved, as well as consequent delivery of the TLR7 agonist to endosomes [83] . Oxidized MWNTs have also been used as delivery system to carry melanoma antigen and CpG ODN adjuvant to DCs and potentiate effective humoral and cellular anti-tumor immunity [84] .
The ability of CNTs to activate complement and the production of several inflammatory cytokines are however major safety concerns when considering CNTs for in vivo delivery of biomaterials [85] [86] [87] .
PLGA
The poly(d,l-lactic-co-glycolic acid) (PLGA) polymer is a biocompatible and biodegradable polymer that has received FDA approval for use as delivery system in humans. PLGA is a co-polymer of poly lactic acid (PLA) and poly glycolic acid (PGA) (Fig. 3) . It is used as suture material with a wellestablished safety profile in humans, and more recently has raised tremendous interest for development of nanoparticulate formulations [68, 88, 89] .
PLGA (x: lactic; y: glycolic) Fig. (3) . Chemical structure of poly-(lactic-co-glycolic) acid, with x standing for the number of lactide monomers and y for the number of glycolide monomers.
Several studies have shown that PLGA micro-and nanoparticles can be used to modulate immune responses against encapsulated antigens, due to their ability to efficiently target professional APCs and to facilitate appropriate processing and presentation of antigens to T cells [68, 90, 91] .
Co-delivery of OVA and MPLA in PLGA nanoparticles to DCs further increased their capacity to activate T cells, in addition to reducing the antigen dose necessary for efficient T cell priming [91] . Studies at the cellular level suggested that PLGA nanoparticles are effective in delivering antigen and MPLA to DCs for induction of CD4 + and CD8 + T cell responses [92] . Some researchers used a new doubleemulsion solvent evaporation method named (TROMS) for encapsulating CpG-chitosan complexes and ovalbumin (OVA) in non-charged PLGA microspheres, thereby maintaining the integrity of both the protein and the CpG ODN. In comparison to microencapsulated OVA alone, coencapsulation of OVA and CpG ODN induced higher antibody titres and in particular an increased production of IgG2a antibodies in the mouse (suggesting a Th1 response) [93] . Also HBcAg-loaded nanoparticles without MPLA [94] . MPLA binds to TLR4 receptor and up-regulates the expression of co-stimulatory molecules on APCs and induce the secretion of cytokines that caused robust immune response [95] . Generation of high IFN-levels and Th1 profile was due to the co-delivery of MPLA and antigen in nanoparticles, since in none of the other conditions a significant IFNproduction was achieved. Another study investigated the correlation between MPLA release from nanoparticles with its adjuvant efficacy [94] . PLGA nanoparticles are appropriate delivery systems for targeting a vast number of TLR analogs and antigens to DCs, allowing us to significantly reduce the effective adjuvant dose [96, 97] . Immunization of mice with PLGA nanoparticles containing antigens plus TLR ligands, such as MPL and R837, induces an enhanced generation of antigen-specific neutralizing antibodies, compared to immunization with single TLR ligands in PLGA nanoparticles or soluble antigen along with MPL and R837, possibly via prolonged stimulation of DCs. Also, it was shown that formulations of antigen and adjuvant in distinct nanoparticles induce a stronger antibody response compared to co-encapsulation in the same nanoparticle [98] .
Evaluation of antibody response by surface plasmon resonance (SPR) showed that immunization with the dual adjuvant formulation could generate antibodies with the highest avidity for their antigen [98] . The safety and potency of PLGA nanoparticles in drug and vaccine delivery is under intensive investigation, despite the fact that the molecular mechanisms responsible for delivery of antigen and adjuvant to the APCs remain elusive.
PEI
Polyethyleneimine (PEI), a cationic polymer, exists in different molecular forms including branched and linear, and with high and low molecular weight [99] . Various forms of PEI act as potent systemic adjuvants, exhibiting greater immunostimulatory activity than alum in sustaining robust antibody production in mice and rabbits [100] . Co-delivery of PEI with CpG ODN synergistically increases the magnitude of the adaptive immune response with a shift toward Th1 response [100] . In vaccination studies using the viral glycoprotein HIV-1gp140, PEI conjugated with CpG ODN induced a Th1 immune response and stimulated the NLRP3 inflammasome in the mouse, although its adjuvant activity was not dependent on such stimulation [100] . While PEI is considered as an efficient transfection agent, there are several reports indicating cellular toxicity caused by PEI through mitochondrial and lysosomal damage, which needs to be taken in consideration when using this material as delivery vehicle [101] [102] [103] [104] .
Liposomes
Liposomes are artificially-prepared spherical vesicles, composed of a lipid bilayer, with sizes ranging between 30 nm to several microns [105] . The liposome lipid bilayer usually consists of synthetic and/or naturally occurring biodegradable phospholipids and cholesterol. The composition of the lipid bilayer determines the liposome physicochemical characteristics, such as size, surface charge and rigidity [105] .
Liposomes have been extensively studied because of their ability to carry both hydrophilic and hydrophobic compounds, as hydrophilic molecules can be encapsulated in the inner aqueous phase, whereas hydrophobic compounds can be dissolved into the lipidic membrane, and amphiphilic ones can partition between both phases [106, 107] . This ability has raised interest in liposomal vaccines, as they are suitable to carry a variety of molecules with different characteristics, such as antigens and immunomodulatory compounds. Furthermore, cationic liposomes facilitate adsorption of negatively charged antigens to their surface, including synthetic peptides, proteins and nucleic acids [108] .
Incorporation of various compounds, e.g., TLRs agonists, can be performed by different methods, such as encapsulation in the aqueous inner space, integration in the bilayer, or surface attachment on the liposome membrane [107, 109] . Enhanced Th1 immune responses have been reported following immunization with CpG ODN encapsulated in liposomes [110] . Liposomes containing MPLA have shown considerable potency and safety as adjuvants with a variety of candidate vaccines, including malaria, HIV-1 and several types of cancer [111] [112] [113] . Administration of liposomes co-delivering poly (I:C) as adjuvant and OVA as antigen causes a robust immune responses [114] . Furthermore, incorporation of aimidazoquinoline derivative, as TLR7-stimulating adjuvant, into cationic liposomes has been shown to potently increase the response to OVA, used as antigen, as compared to the non-encapsulated adjuvant [115] .
VLP
Among the most interesting nano-based particles are virus-like particles (VLPs), which can be designed in various sizes and structures [116] . They can be used as antigen carriers in the development of vaccines for both infectious and non-infectious diseases [116] . Based on their structure and manufacturing, VLPs are categorized into two distinct groups, virus-derived and synthetic particles [117] . Due to the lack of genetic material, VLPs are safe, as they are unable to replicate in the host cells. A major advantage is that they can be extensively manipulated to incorporate diverse ligands targeting TLRs and other PRRs [117] . In this regard, results from clinical trials indicate that delivery of TLR9 agonists (CpG-ODNs) and melanoma-derived antigens with VLPs results in suppression of tumor growth via activation of CTLs and production of Th1-associated cytokines such as IFN-and TNF- [117] . Up to now, two VLP-based vaccines have been developed and approved, against viral infections caused by HBV and HPV [118] . It has been demonstrated that incorporation of viral-derived recombinant proteins into VLP can prophylactically inhibit HBV and HPV infections, while the same vaccines do not have therapeutic effect in established infections [118] .
MULTIPLE DELIVERY SYSTEMS CARRYING MULTIPLE PRR AGONISTS
During the natural infection, most pathogens present multiple PAMPs to stimulate multiple PRRs, resulting in a synergistic up-regulation of inflammatory cytokine production, activation of APCs, and induction of strong immune responses. Therefore, the combination of multiple PRR agonists and proper delivery systems may be a promising strategy to induce strong immune responses in the context of vaccine development [119] . The co-delivery of multiple TLR agonists and antigens by co-encapsulation in nanoparticles such as PLGA is an efficient strategy to increase the strength and modulate the quality of the immune response against antigens [120] . We have developed a nanoadjuvant based vaccine delivery system, in which multiple delivery platforms were used in combination with multiple TLR agonists. In this study, SWNTs were covalently conjugated to PEI, using amide chemistry, followed by addition of CpG ODN as TLR9 agonist.Furthermore, MPLA as TLR4 agonist and imidazoquinoline as TLR7/8 agonist were co-encapsulated in PLGA in order to produce nanoparticulate adjuvants, while the OVA protein as antigen was encapsulated in PLGA. The in vivo administration of these nano-adjuvant complexes in mice generated robust antibody and cytokine production exhibiting mixed Th1/Th2 immune responses (Ebrahimian et al., submitted).
CONCLUDING REMARKS & FUTURE PERSPECTIVES
Progress in the design and construction of novel nanomaterial-based delivery systems is allowing us to target the delivery of multiple immunostimulatory compounds to the intracellular compartments of desired cell types. In spite of many experimental results showing immunostimulatory functions, only few nano-compounds have succeeded to get licensed for human use. Likewise, many nanomaterials have shown potential adjuvant activity, but did not reach applicability for several reasons including instability, high cost in manufacturing, and serious concerns regarding host tolerability and safety.
To achieve a vaccine formulation with optimized protective or therapeutic functions, the use of adjuvants possessing immunostimulatory properties and facilitating delivery is a critical issue. Nanotechnology-based approaches have led to the development of nano-scale materials with excellent adjuvant activity [121] . Nanomaterials have properties that allow us to stimulate both innate and adaptive immunity by targeting a wide array of surface receptors. Therefore, at variance with classical adjuvants such as alum that predominantly induces the humoral arm of immunity, nanomaterial-based adjuvants could allow us to induce different types of immune responses, simply by manipulating particle size and surface characteristics and by decorating the particles with immunostimulatory and immunomodulatory agonists [122] . Nanomaterials can be easily modified to coincorporate both vaccine-specific antigens and PRR ligands as adjuvants. Targeting multiple PRRs by such carriers, which are able to co-deliver and control the release of stimuli, can achieve optimal activation of APCs [123] . Nanoparticles can be tuned on the basis of pathogens structures, which are highly effective in eliciting optimal immune responses. Thus, a promising strategy to provide strong and long-lasting immunity against infectious diseases, implies integrating PRR agonists and antigens in delivery systems resembling pathogen size and shape [9, 10] . Although significant progress has been achieved in the nano-based vaccine research area, there are unknown issues that need to be considered in future studies. For example, more data should be provided concerning the molecular events taking place during the interaction between nanomaterials and immune cells. Also, we need to understand how nano-based adjuvants should be formulated to optimize APC activation in the context of long-term immune memory responses. To achieve such developments, exploiting various highthroughput assays could be of great help to scrutinize precise intracellular interactions. In addition, more preclinical research is needed, focusing on the effects of structure, size and charge of nano-delivery systems on the immune cells, in order to facilitate the development of effective nano-based approaches to human and veterinary vaccination.
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